Core Viewpoint - K2 Capital Acquisition Corp. announced that starting February 25, 2026, holders of its 13,800,000 units from the initial public offering can separately trade Class A ordinary shares and rights included in the units [1] Group 1: Offering Details - The units were offered in an underwritten offering, with D. Boral Capital acting as the sole book-running manager [2] - A registration statement on Form S-1 was declared effective by the SEC on January 28, 2026, and the offering is made only by means of a prospectus [2] Group 2: Trading Information - Units not separated will continue to trade on NASDAQ under the symbol "KTWOU," while separated Class A ordinary shares and rights will trade under the symbols "KTWO" and "KTWOR," respectively [1] - Holders must contact the Company's transfer agent, VStock Transfer, to separate their units into Class A ordinary shares and rights [1] Group 3: Company Overview - K2 Capital Acquisition Corp. is a blank check company, also known as a special purpose acquisition company (SPAC), formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [4]

目前，该公司在海口市运营着四家全方位服务的 4S 店，并已与吉利几何、长城欧拉、奇瑞新能源及广 汽传祺等中国主流新能源汽车品牌建立了深度代理合作关系。随着海南省加速推进"全岛禁售燃油车"的 战略目标，奥创控股正试图利用政策红利进一步巩固其在区域市场的竞争地位。 奥创控股成立于2013年，计划在纳斯达克上市，股票代码为ANE。D. Boral Capital担任此次交易的唯一 簿记管理人。 奥创控股此次大幅调增发行股数，其核心目的在于满足纳斯达克交易所更为严格的上市准入门槛。根据 现行规定，拟上市企业必须确保其公众流通市值(Minimum Public Float)至少达到1500万美元。 作为海南省内领先的乘用电动汽车(EV)零售服务商，奥创控股业务涵盖了新车销售、售后维修、零配件 供应以及汽车金融和保险等全链条服务。 智通财经APP获悉，周二，中国电动汽车零售商奥创控股(ANE.US)提高了其即将进行的首次公开募股 (IPO)的拟议交易规模。这家总部位于中国海口的公司目前计划以每股4至6美元的价格区间发行600万股 股票，筹集3000万美元。该公司此前曾申请以相同价格区间发行130万股股票。按发行价区间的中 ...

Core Viewpoint - K2 Capital Acquisition Corporation has announced the pricing of its upsized initial public offering (IPO) of 12,000,000 units at $10.00 per unit, with each unit consisting of one Class A ordinary share and one right to receive one-fifth of one Class A ordinary share upon the closing of the initial business combination [1] Group 1: IPO Details - The units are expected to trade on the Nasdaq Global Market under the ticker symbol "KTWOU" starting January 29, 2026 [1] - The company has granted underwriters a 45-day option to purchase up to 1,800,000 additional units at the IPO price to cover over-allotments [2] - The IPO is expected to close on January 30, 2026, subject to customary closing conditions [2] Group 2: Legal and Regulatory Information - A registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission on January 28, 2026 [3] - The offering is being made only by means of a prospectus, which can be obtained from D. Boral Capital or the SEC's website [3] Group 3: Company Overview - K2 Capital Acquisition Corporation is a blank check company, also known as a special purpose acquisition company (SPAC), formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [5]

Core Insights - Enlivex Therapeutics Ltd. will participate in a live investor webinar discussing advancements in the treatment of inflammatory diseases, specifically focusing on knee osteoarthritis [1][2][7] Company Overview - Enlivex is a clinical-stage company specializing in macrophage reprogramming immunotherapy, developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to restore immune balance [8] Webinar Details - The webinar is scheduled for September 30, 2025, at 10:00 AM Eastern Time, featuring key opinion leaders in musculoskeletal disease and Enlivex's Vice Chairman [1][3] - The discussion will highlight positive Phase IIa topline data from the Allocetra™ program, showing significant pain reduction and functional improvement in patients with moderate-to-severe knee osteoarthritis [2][7] Expert Panel - The panel includes notable experts such as Professor Ali Mobasheri, Professor Philip Conaghan, Dr. Roger Pomerantz, and Jason Kolbert, each bringing extensive experience in musculoskeletal health and clinical research [3][4][5][6] Clinical Significance - The Phase IIa data from the Allocetra™ program indicates a strong potential to change the treatment landscape for knee osteoarthritis, a condition currently lacking approved disease-modifying therapies [2][7]

As filed with the U.S. Securities and Exchange Commission on July 23, 2025. Registration No. 333-286810 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 (I.R.S. Employer Identification Number) 10 E. 53rd Street, Suite 3001 New York, NY 10022 Telephone: (332) 266-7344 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) David Boral Chief Executive Officer 10 E. 53rd Street, Suite 3001 New York, ...

As filed with the U.S. Securities and Exchange Commission on June 6, 2025 Registration No. 333-286569 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________________ Yorkville Acquisition Corp. (Exact name of registrant as specified in its charter) ___________________________________ | | | (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial C ...

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 D. Boral ARC Acquisition I Corp. (Exact name of registrant as specified in its charter) As filed with the U.S. Securities and Exchange Commission on April 28, 2025. Registration No. 333-_____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (State or other jurisdiction of incorporation or organization) British Virgin Islands 6770 N/A (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...